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Distal hereditary motor neuropathies comprise a clinically and genetically heterogeneous group of disorders. We recently mapped an
X-linked form of this condition to chromosome Xq13.1-q21 in two large unrelated families. The region of genetic linkage included
ATP7A, which encodes a copper-transporting P-type ATPase mutated in patients with Menkes disease, a severe infantile-onset neurode-
generative condition. We identiﬁed two unique ATP7Amissense mutations (p.P1386S and p.T994I) in males with distal motor neurop-
athy in two families. These molecular alterations impact highly conserved amino acids in the carboxyl half of ATP7A and do not directly
involve the copper transporter’s known critical functional domains. Studies of p.P1386S revealed normal ATP7A mRNA and protein
levels, a defect in ATP7A trafﬁcking, and partial rescue of a S. cerevisiae copper transport knockout. Although ATP7Amutations are typi-
cally associated with severe Menkes disease or its milder allelic variant, occipital horn syndrome, we demonstrate here that certain
missense mutations at this locus can cause a syndrome restricted to progressive distal motor neuropathy without overt signs of systemic
copper deﬁciency. This previously unrecognized genotype-phenotype correlation suggests an important role of the ATP7A copper trans-
porter in motor-neuron maintenance and function.Introduction
The distal hereditary motor neuropathies (distal HMNs)
comprise a clinically and genetically heterogeneous group
of disorders predominantly affecting motor neurons in the
peripheral nervous system.1 Affected distal HMN individ-
uals manifest progressive weakness and wasting beginning
in the distal muscles of the limbs and have no notable
sensory symptoms. Distal HMNs have been classiﬁed
into seven subgroups based on mode of inheritance, age
of onset, distribution of muscle weakness, and clinical
progression.2 Fifteen genetic loci for distal HMN have
been mapped, and eight genes have been identiﬁed.3
These encode a functionally diverse array of gene products,
including a transfer RNA synthetase,4 two heat-shock
proteins,5,6 and a microtubule motor protein involved
in axonal transport.7 A form of distal HMN with linkage
to chromosome Xq13.1-q21 (DSMAX; SMAX3 [MIM
300489]) was reported in a Brazilian family.8 We recently
mapped and reﬁned this locus in a second unrelated North
American family of European descent.9 The 14.2 Mb
region containedmore than 50 annotated genes, including
ATP7A (MIM 300011), which encodes a copper-transport-
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The AmeriCopper is an essential trace metal with potential toxicity
and requires exquisite homeostatic control; its regulation
involves mechanisms governing gastrointestinal uptake,
transport to the developing brain, targeted intracellular
delivery to copper enzymes, and hepatic excretion of cop-
per into the biliary tract.10–13 These functions are largely
fulﬁlled by a pair of evolutionarily related copper-trans-
porting ATPases, ATP7A and ATP7B (MIM 606882). The
ATP7A gene is mutated in Menkes disease (MK; MNK
[MIM 309400]), a severe infantile-onset developmental
disorder.14–17 An allelic variant, occipital horn syndrome
(OHS [MIM 304150]), is similar in many clinical and
biochemical aspects, although the neurologic phenotype
is far less severe.18,19 Neither condition features overt
motor neuropathy.
In this study, we evaluated the ATP7A copper transporter
in two families whose affected members had X-linked
distal motor neuropathy.
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Figure 1. Inheritance Pattern and Clin-
ical Findings in X-Linked Distal Motor
Neuropathy
(A) Pedigrees of family A, modiﬁed from
Kennerson et al.,9 and family B, modiﬁed
from Takata et al.8 The pedigrees show
the key branches of the families with
affected individuals. Squares indicate
males, and circles indicate females. Solid
symbols denote affected family members,
and open symbols denote unaffected
family members. The hatched circle (III-4
in family A) indicates an asymptomatic
female with minimal clinical signs of
motor neuron disease. Internal dots indi-
cate obligate gene carriers. Asterisks denote
individuals who are conﬁrmed carriers of
the gene mutations and were examined
by one ormore of the authors in this study.
Diagonal lines through symbols indicate
deceased individuals.
(B) Clinical ﬁndings in X-linked distal
motor neuropathy. Evidence of distal
muscle wasting in a 43-year-old male
(IV-2, family A; Figure 1A) with the
P1386S ATP7A mutation. Both legs
showed decreased mass of the vastus later-
alis (VL), vastus medialis (VM), tibialis ante-
rior (TA), gastrocnemius (G), and soleus (S)
muscles. Both feet showed pes cavus defor-
mities. There was moderate wasting of the
ﬁrst dorsal interosseus (open arrows) and
the hypothenar (arrow) muscle groups of
the hand. The patient’s hair was normal
in texture and had no pili torti under light
microscopy. The palate showed normal
contour. The thorax showed no defor-
mities, and the cardiac and pulmonary
examinations were normal. The joints
and skin did not show excessive laxity.
Radiographic studies showed no wormian
bones of the skull, no occipital exostoses,
and normal clavicular heads. Plasma cate-
cholamine ratios and the urine concentra-
tion of beta-2-microglobulin, biomarkers
often elevated in Menkes disease,22 were
normal.and family B (Brazilian) (Figure 1A) demonstrated X-linked inher-
itance of a distal motor neuropathy phenotype (Figure 1B)
deﬁned by decreased motor action potentials, normal nerve
conduction velocities, and limited or no sensory involvement.1
Both families are of European descent. A total of 31 individuals
from family A and 30 individuals from family B were examined
for neurological signs. Clinical, biochemical, and electrophysio-
logic ﬁndings in affected members of these families are summa-
rized (Table 1). The ethics review committees of all participating
institutions approved the study, and written informed consent
was obtained from subjects or parents of subjects less than
18 years of age.
Mutation Analysis
Genomic DNA was isolated from blood samples using standard
protocols or saliva samples using the Oragene Kit (DNA Genotek).
Mutation analysis was performed using high resolution melt
protocols established in our laboratory.9 PCR amplicons for muta-
tion scanning were designed to cover the coding exons and ﬂank-
ing intronic sequences. Primers for all genes including the ATP7A344 The American Journal of Human Genetics 86, 343–352, March 1gene were designed using the LightScanner Primer Design
Software (version 1.0.R.84 Idaho Technology). Melt acquisition
was performed on a 96-well Light Scanner (Idaho Technology)
and the data analyzed with Light Scanner Call-IT 2.0 (Version
2.0.0.1331). Amplicons of differential melt curves were sequenced
using BigDye Terminator Cycle Sequencing protocols at the ACRF
Facility, Garvan Institute of Medical Research, Australia.
Cell Culture
Human ﬁbroblast cells obtained by skin biopsies from affected
patients from family A and B, a Menkes disease patient with dele-
tion of ATP7A exons 20–23, a normal healthy male, and the ﬁbro-
blast cell line GM3652 from the American Type Culture Collection
(Rockville, MD) were grown in Dulbecco’s modiﬁed Eagle’s
medium containing 10% (v/v) fetal bovine serum under humidi-
ﬁed air at 37C in 5% CO2. Experimental variations in culture
media or temperature are indicated in the text, ﬁgures, or legends
where relevant. Copper concentrations in ﬁbroblast tissue extracts
were determined by inductively coupled plasma mass spectrom-
etry as previously described.202, 2010
Table 1. Clinical, Neurophysiologic, and Biochemical Features in Study Subjects
Family/
Patient
Age
(yr)
Onset
(yr) Weakness Atrophy
Sensory
Exam DTRs
Median
CMAP
(mV)
Median
NCV
(m/s)
Tibial
CMAP
(mV)
Median
SNAP
(mV)
Serum Cu
(nmol/
liter)
A/III-4 52 ~50 Mild distal L > A Mild H Normal Absent
Achilles
NR NR NR NR NR
A/IV-1 22 ~4 Moderate
distal L, mild H
F, mild H Normal Absent
Achilles
4.3 57.6 1.9 13.3 NR
A/IV-2 43 ~15 Distal, L > A F, lower L, H Mild distal
toes, ﬁngers
Absent
Achilles
2.62 61.5 2.80 26.6 15.4
A/IV-3 44 10 Distal, L > A F, Distal L, H Mild distal
lower L
Absent
Achilles
3.6 46.8 NR 17 NR
A/IV-6 62 61 Mild distal L Mild distal L, F Mod. distal L
vibratory loss
Absent
Achilles
NR NR 2.73 NR 13.2
A/IV-7 53 30 Mild L > A H, F Normal Normal 12.0 57.5 2.3 NR 12.5
A/IV-12 57 10 Distal L > A F, distal L,H Mild distal L
reduction
Normal 0.03 0 0 NR NR
A/V-1 16 13 Mild distal L None Normal Normal 6.3 64.7 13.5 NR NR
A/V-2 41 35 Distal L Mild F atrophy Mild distal L
sensory loss
Normal 2 NR NR NR NR
A/V-3 33 25 Mild H Mild H Normal Normal 8.0 56.8 4.8 NR NR
B/IV-2 26 8 Distal L Moderate distal A,L Normal Absent L 2.7 50.5 NR 25.8 15.3
B/IV-3 29 2 Distal L, A Severe distal L,F,H Normal Areﬂexic 0.33 41.2 0.07 66.0 13.4
B/V-1 5 Absent Absent Normal Normal NR NR NR 62.0 NR
Reference Ranges
R4 R50 R4 >20 11-23.622
Abbreviations are as follows: L, leg; F, foot; H, hand; A, arm; DTR, deep tendon reflexes; CMAP, compound motor action potential; SNAP, sensory nerve action
potential NR, not recorded. Reference ranges for neurophysiological measurements are from Clinical Neurophysiology.47Real-Time Quantitative PCR
Total RNA was isolated using the QIAGEN RNeasy Mini Kit
(QIAGEN). cDNAwas generated from 5 mg RNAwith AfﬁnityScript
reverse transcriptase (Stratagene). Quantitative real-time PCR was
performed with speciﬁc primers for ATP7A (50-GCTACCTTGTCAG
ACACGAATGAG-30 and 50-TCTTGAACTGGTGTCATCCCTTT-30)
and b-actin (50-GACAGGATGCAGAAGGAGATTACT-30 and 50-TG
ATCCACATCTGCTGGAAGGT-30) as previously described.21Immunoblot Analysis
Total cell lysates were denatured by the addition of 53 loading
bufferwith5%b-mercaptoethanol (QualityBiological) andheating
at 50C for 10min. Samples (40 mg total protein) were electrophor-
esed through 4%–12% NOVEX Tris-glycerin SDS-poly-acrylamide
(Invitrogen)and transferred topolyvinylidineﬂuoridemembranes.
Membraneswere incubated at 4Covernight in Tris-buffered saline
blocking buffer (0.9% (v/v) NaCl, 20 mM Tris/HCl [pH 7.5], 0.5%
SDS (v/v), 0.1% Tween 20 v/v) containing 5% (w/v) nonfat milk.
Blots were washed three times for 5 min each with Tris-buffered
saline, then incubated for 3 hr with a 1:1000 dilution of a rabbit
ATP7A antibody raised against the carboxy-terminal 18 amino
acids (NH2-DKHSLLVGDFREDDDTAL-COOH) of human ATP7A
(Antibody Solutions). After being washed, membranes were incu-
bated with anti-rabbit IgG horseradish peroxidase conjugate
(1:2000, Santa Cruz Biotechnology) for 1 hr at room temperature,
washed again, and developed with SuperSignal West Pico Lumi-
nol/Enhancer Solution (Pierce) according to the manufacturer’sThe Ameriinstructions. After membranes were stripped, incubation with
a primary mouse anti-b-actin monoclonal antibody conjugated
with horseradish peroxidase (Santa Cruz Biotechnology) was per-
formed so that b-actin could be detected; an enhanced chemilumi-
nescence reagent was used for development, as above.
Immunohistochemical Analysis and Confocal
Microscopy
Dermal ﬁbroblasts were ﬁxed on glass slides with 4% (w/v) parafor-
maldehyde. Blocking was performed with 3% (v/v) goat serum at
room temperature for 1 hr. Samples were incubated with the rabbit
anti-human carboxy-terminal ATP7A primary antibody (described
under Immunoblot Analysis) at a dilution of 1:2000 at 4C over-
night; subsequently, Texas Red-labeled anti-rabbit IgG antibody
(Molecular Probes) was used as the secondary antibody for incuba-
tion at room temperature for 2 hr. Cells were viewed with a
confocal microscope (Nikon Eclipse, Nikon), and images captured
with Confocal Assistant software.
ATP7A Trafﬁcking
Fibroblasts were grown in duplicate on 12 mm glass coverslips in
24-well trays and cultured at 30C for 16 hr. The growth media
were replaced with either basal media (0.51 mM copper) or media
supplemented with 200 mM CuCl2 for 3 hr. Fibroblasts were then
ﬁxed with 4% (w/v) paraformaldehyde in PBS for 10 min, permea-
bilized with 0.1% Triton X-100 in PBS for 10 min, and blocked
with 1% BSA and 0.25% gelatin in PBS at room temperaturecan Journal of Human Genetics 86, 343–352, March 12, 2010 345
for 20 min. Cells were incubated with the sheep anti-human
N-terminal ATP7A antibody21 and a mouse monoclonal antibody
to the trans Golgi marker p230 (BD Transduction Laboratories)
diluted 1:1000 and 1:500, respectively, in 1% BSA at 4C overnight
and then with the secondary antibody, Alexa Fluor 488 (green)
donkey anti-sheep IgG (Molecular Probes) (1:4000) or Alexa Fluor
594 (red) donkey anti-mouse IgG (Molecular Probes) at room
temperature for 1 hr. Confocal images were collected with a Leica
confocalmicroscope system TCS SP2 (Leica). As a semiquantitative
assessment, normal control and affected patient ﬁbroblasts were
scored for ATP7A staining in the transGolgi after copper exposure,
and chi square analysis was used for statistical comparison. The
trafﬁcking experiments were performed in quadruplicate.Yeast Complementation
Site-directed mutagenesis was performed as described19,22 for
generation of the P1386S ATP7A mutant allele. Plasmid DNA
from the yeast expression vector del20-23/pYES22 containing
bases 1–3800 of the ATP7A cDNA was double-digested with SpeI
and SacI so that a 523 bp fragment containing a KpnI restiction
site would be removed from the plasmid sequence. The fragment
was replaced by a 511 bp fragment without the KpnI site via
PCR of pYES DNA with primers 50GCGACTAGTACGGATTAGA
AGCCGCCGAGCGGGTGACAGCCCTCC-30 (forward) and 50-CG
CGAGCTCAATATTCCCTATAGTGAGTCGTATTACAG-30 (reverse);
T4 DNA ligase and an insert-to-vector ratio of 1.6:1 (35 fmoles:
22 fmoles) were used. The construct generated from this cloning
was named del20-23/pYES/sKs (single KpnI site). A 501 bp frag-
ment of the ATP7A cDNA then was excised from del20-23/pYES/
sKs via double digestion with KpnI and ApaI, replaced with
a 1201 bp fragment containing the P1386S mutation (C-to-T tran-
sition), and named P1386S/pYES/sKs. DNA ﬁdelity was conﬁrmed
by automated sequencing. Yeast complementation and timed
growth assays were carried out as previously described19,22 except
that plates and liquid media contained 100 mg/ml blasticidin.Results
Gene Mutation Analysis
Thirty-three genes that underwent mutation analysis in
this study are shown in Figure 2A. High-resolution melt
analysis of ATP7A exon 22 showed differential subtractive
melt curves between affected male/carrier female and
normal male/noncarrier female groups in family A (Fig-
ure 2B). Sequence analysis of nine affected males identiﬁed
a transitionmutation of c.4156C> T in exon 22 (Figure 2C,
family A), which predicts an amino acid substitution of
p.P1386S. The alteration was not present in seven unaf-
fected male members from family A. ATP7Awas sequenced
in ten affected males from family B, and a transition muta-
tion of c.2981C > T in exon 15 was identiﬁed (Figure 2C,
family B), predicting a p.T994I amino acid substitution.
The alteration was not present in six unaffected males
from family B. The p.P1386S and p.T994I, alterations
were absent from 800 unrelated, ethnically matched con-
trol chromosomes. The documented mutations all occur
in the carboxyl half of the ATP7A protein (Figure 3A) and
are highly conserved (Figure 3B).346 The American Journal of Human Genetics 86, 343–352, March 1P1386S ATP7A RNA and Protein Analysis
We used quantitative RT-PCR and immunoblotting to
determine whether mRNA and protein levels were altered
in P1386S ﬁbroblasts. The level of mRNA expression was
not signiﬁcantly changed (Figure 4A), and immunoblot
analyses of ﬁbroblast protein extracts (Figure 4B) showed
a similar amount and size of the protein when these were
compared to normal controls.
Immunocytochemical and Biochemical Analyses
and Trafﬁcking of P1386S ATP7A Protein
In cultured mammalian cells, ATP7A localizes to the trans
Golgi network in basal copper concentrations22,23 and
relocates to small vesicles and the plasma membrane
in cells exposed to elevated copper.23 Immunocytochemi-
cal analyses revealed correct trans Golgi localization of
ATP7A in ﬁbroblasts cultured at 37C under basal copper
conditions (Figure 4C, middle panel), whereas the steady-
state ﬁbroblast copper levels in P1386S ﬁbroblast cell lines
were intermediate between those in a normal control and
a classical Menkes disease patient: ﬁbroblasts from IV-2
and V-3 from family A contained 214.36 mg Cu/g dry
weight5 3.64 standard deviation (sd) and 118.08 mg Cu/g
dry weight5 6.97 SD, respectively, versus 84.125 0.67 in
the GM3652 normal cell line and 540.34 5 19.45 SD in
the del ex20–23 ﬁbroblasts from a patient with Menkes
disease22. Increased copper retention is characteristic of
cultured ﬁbroblasts from patients with Menkes disease
and occipital horn syndrome,18 reﬂecting reduced capacity
for copper exodus across the plasma membrane.
WhenweculturedP1386Sﬁbroblasts at 30Ctoassess the
possibility of a conditional (temperature-sensitive) muta-
tion,24,25 we observed impaired ATP7A trafﬁcking in
response to copper loading in these P1386S ﬁbroblasts
compared to normal ﬁbroblasts (Figure 4D). Under basal
copper conditions, the wild-type and mutant protein both
showed extensive colocalization with the trans Golgi
marker p230 (Figures 4D and 4Dh). After a 3 hr exposure
to 200 mM copper, wild-type ATP7A was completely absent
from the trans Golgi (Figure 4Dl), whereas the P1386S
mutant protein remained substantially colocalized with
the trans Golgi marker (Figure 4Dp). To conﬁrm this obser-
vation, we scored 48 cells for the presence of ATP7A in the
trans Golgi after copper exposure. This semiquantitative
evaluation indicated that 24/27 (89%)P1386S cells retained
ATP7A in the transGolgi, as compared to3/21 (14%)normal
control cells (p < 0.0001). We also conﬁrmed the presence
of this trafﬁcking abnormality in cultured T994I ﬁbroblasts
(Figure S1), which represents a delay in the expectedmove-
ment of ATP7A-laden vesicles from the transGolgi network
to the plasma membrane after copper exposure.
Yeast Complementation Studies
We also employed a yeast complementation assay19,22 to
assess the capacity of the P1386S mutant allele to comple-
ment an S. cerevisiae copper-transport knockout, ccc2D.
This assay measures the capacity of human ATP7A to2, 2010
Figure 2. Genetic Basis of X-linked Distal Motor Neuropathy
(A) Display of annotated genes in the interval between the markers DXS8046 and DXS8114; data are from the University of California
Santa Cruz (UCSC) Genome Browser (HumanMarch 2006 Assembly; NCBI Build 36.1). Redundant genes are not shown, and the coding
region of genes formally excluded in family A are shaded. An asterisk denotes the ATP7A gene, which maps between PGAM4 and PGK1.
High-resolution melt analysis was used for scanning all genes except for HDAC8, RLIM, and PGAM4, which underwent sequence anal-
ysis.9
(B) Subtractive difference plot for affected/carrier and normal/noncarrier samples in family A for exon 22 of ATP7A. The differential
shape and grouping of affected/carrier and normal/noncarrier difference plots suggested that a DNA variant was segregating with the
distal motor neuropathy phenotype in this family.
(C) Sequence data in affected males, carrier females, and normal males for p.P1386S and p.T994I. An asterisk denotes the base change
resulting in missense mutations that segregate with distal motor neuropathy in the respective families. The GenBank sequences
NM_00052 and NP_000043.3 were used as the reference sequences for the ATP7A cDNA and the ATP7A protein, respectively. Mutations
are designated on the basis of numbering of the A in the ATG translation initiation site as þ1.replace the function normally performed by the ATP7A
ortholog ccc2; speciﬁcally, this function is the delivery of
copper to Fet3, a copper-containing protein required for
high-afﬁnity iron uptake.26 On copper- and iron-deﬁcient
solid media, the P1386S allele complemented ccc2D at
22, 25, 30, and 37C, whereas the ATP7A deletion allele,
del ex20–23, did not (data not shown). To quantify the
relative amount of residual copper-transport activity, we
utilized a standard timed growth assay19,22,27–29 in copper-
and iron-deﬁcient liquid media at the four temperatures.The AmeriThe growth of ccc2D transformed with the P1386S allele
was less than wild-type growth at all temperatures (Fig-
ure 5). At 30C, the standard optimal temperature for yeast
cell growth, the calculated copper-transport capacity of
P1386S in ccc2D during exponential phase growth was
70% relative to that in ccc2D transformed by the wild-
type ATP7A (Figure 5C). There was no further diminution
in P1386S residual functional activity relative to the wild-
type when the assay was performed at lower temperatures
(22C and 25C, Figures 5A and 5B). As expected, ccc2Dcan Journal of Human Genetics 86, 343–352, March 12, 2010 347
Figure 3. Locations and Sequence Align-
ments of ATP7A Mutations Causing Distal
Motor Neuropathy
(A) Topological depiction of the p.T994I
and p.P1386S mutations in the ATP7A
copper-ATPase associated with distal
hereditary motor neuropathy.
(B) Alignment analysis of the p.T994I and
p.P1386S mutations for ATP7A orthologs
in different species. Amino acid positions
994 and 1386 are boxed.transformed with the del ex20–23 ATP7A allele (Figure 5,
orange lines and triangles) grew poorly in the timed
growth assay at all temperatures.Discussion
Our ﬁndings reveal a third clinical phenotype associated
with mutations in the ATP7A copper transporter gene,
which was shown previously to cause Menkes disease14–
16 and occipital horn syndrome.18 This new allelic variant
involves progressive distal motor neuropathy with mini-
mal or no sensory symptoms. Affected patients with the
distal motor neuropathy discussed here do not manifest
the severe infantile central neurological deﬁcits observed
in Menkes disease, the signs of autonomic dysfunction
seen in occipital horn syndrome, the hair and connec-
tive-tissue abnormalities found in both conditions, or
any of the clinical biochemical features of those well-char-
acterized phenotypes.17–19,22 These ﬁndings highlight the
phenotypic distinction between this isolated distal motor348 The American Journal of Human Genetics 86, 343–352, March 12, 2010neuropathy and the syndromes previ-
ously associated with ATP7A muta-
tions. By comparison of the molec-
ular bases, Menkes disease is caused
by profound loss-of-function muta-
tions, including deletions, splice-site
mutations at canonical positions,
nonsense mutations, and missense
mutations that affect a critical func-
tional domain in ATP7A or induce
misfolding,14–16,25,28,30 whereas oc-
cipital horn syndrome is associated
with molecular defects that allow
considerable residual copper trans-
port, often via leaky splice-junction
mutations involving noncanonical
bases.18,19,30 In contrast, the missense
mutations we describe here do not
disrupt critical functional domains,
disturb proper splicing, or cause
reduced levels of ATP7A protein
(Figure 4B). They occur in exons 15
(p.T994I) and 22 (p.P1386S), loca-
tions in which ATP7Amissense muta-tions appear to be exceedingly rare.30 The phenomenon of
late, often adult-onset, distal muscular atrophy implies
that these mutations produce somewhat attenuated effects
that require years to provoke pathological consequences.
The aberrant ATP7A trafﬁcking in P1386S and T994I ﬁbro-
blasts, the copper-retention phenotype in P1386S ﬁbro-
blasts that is intermediate between normal and classical
Menkes disease, and the partial complementation of the
ccc2D copper-transport knockout by the P1386S allele are
all consistent with this hypothesis.
It is known that individuals with acquired copper deﬁ-
ciency due to excess zinc ingestion, malabsorption, gastric
bypass surgery, or nephrotic syndrome can develop myelo-
neuropathy involving a profound sensory ataxia that
improves or stabilizes in response to copper repletion.31–35
Signs of lower motor-neuron disease, including proximal
and distal muscle weakness and bilateral foot drops, have
also been reported in copper-deﬁcient individuals.36 Taken
together with these reports, our molecular, clinical, and
biochemical ﬁndings suggest that motor neurons might be
particularly sensitive toperturbations incopperhomeostasis.
Figure 4. Characterization of P1386S
ATP7A
(A) Quantitative RT-PCR showing ATP7A
mRNA levels from P1386S ﬁbroblasts rela-
tive to control ﬁbroblasts from a normal
individual. The error bars indicate stan-
dard deviation. Each sample was run in
triplicate.
(B) Immunoblot showing the proper size
(z178 kDa) and amount of ATP7A from
P1386S ﬁbroblasts relative to a normal
control (ﬁbroblast cell line GM3652).
A negative control (ﬁbroblast protein
with deletion of exons 20–23 from a
patient with Menkes disease22) shows no
detectable ATP7A. Lower panel: beta-actin
control for loading.
(C) Immunocytochemistry for subcellular
localization of P1386S ATP7A at 37C in
basal copper levels. Arrows show anti-
ATP7A signal (red) with a perinuclear dis-
tribution consistent with trans Golgi local-
ization in normal and P1386S ﬁbroblasts.
No antibody signal is evident in a del
ex20–23 ﬁbroblast cell. Cells were grown
in media with normal copper concentra-
tion (0.5 mM) at 37C and immunostained
with an antibody against the carboxyl
terminus of ATP7A. The scale bar repre-
sents 10 mm.
(D) Effect of temperature and copper con-
centration on the intracellular localization
of ATP7A at 30C. In 0.5 mM copper, both
wild-type (a and c) and P1386S mutant
(e and g) ATP7A (green in these panels)
show extensive colocalization with the
p230 trans Golgi marker (red in panels
b and f) overlay in c and g. In 200 mM
copper, the wild-type ATP7A shows traf-
ﬁcking out of the trans Golgi (i) and shows
little localization with p230 (overlay in k).
In contrast, the mutant P1386S did not
show much movement out of the trans
Golgi (m), and extensive perinuclear
yellow remains, indicating colocalization
with the p230 marker (o). Further demon-
strating the difference in trafﬁcking, cells
indicated by the yellow arrows were
enlarged and are shown in panels d, h, l,
and p. Panels d and h clearly show the
extensive areas of colocalization of both
the wild-type and P1386S ATP7A in 0.5 mM
copper. Panel l shows the complete traf-
ﬁcking of ATP7A out of the trans Golgi;
only the red staining of p230 remains.
Panel p shows extensive areas of yellow,
indicating that much of the mutant
ATP7A remains in the trans Golgi. Photo-
graphs were taken with a 633 objective
lens on a Leica TCS SP2 confocal micro-
scope. The scale bar represents 40 mm.The precise nature of such perturbations remains to be
elucidated. The abnormal trafﬁcking of mutant ATP7A in
ﬁbroblasts at 30C raises the possibility that these variants
represent a new class of cold-sensitive mutations, although
clinical evidence of thermal sensitivity is not overtly
apparent in affected individuals from these families.8,9
A previously studied temperature-sensitive ATP7AThe Amerimissense mutation involved abnormal intracellular locali-
zation due to proteinmisfolding, which was ameliorated at
a lower temperature (30C).25 Because the P1386S and
T994I trafﬁcking defect is clearly not improved at lower
temperatures (Figure 4D and S1), protein misfolding seems
unlikely to explain the impact of these two mutations.
The absence of dramatic temperature effects in the yeastcan Journal of Human Genetics 86, 343–352, March 12, 2010 349
Figure 5. Effects of Temperature on Yeast Complementation by P1386S ATP7A
For each of the temperatures noted ([A] 22C, [B] 25C, [C] 30C, [D] 37C), cell densities (OD600) of shaking liquid culturesweremeasured
at0,2,4, and6hr for theSaccharomyces cerevisiaecopper transportmutant, ccc2D transformedwith thewild-type (WT)ATP7Aallele (blue),or
ATP7A alleles harboringP1386S (red), a deletionof theATP7A carboxyl-terminal four exons, del 20–23 (orange), andnontransformed ccc2D
(green). Error bars denote51 standard deviation from themean of quadruplicateOD600measurements. The growthof ccc2D transformed
with the P1386S allelewas less than that of ccc2D transformedwith thewild-type allele at all temperatures tested.Growth of these twoyeast
transformants was suboptimal at 22C, 25C, and 37C compared to 30C. At 30C, P1386S complemented the ccc2D knockout strain at
70% of the wild-type rate. Residual copper transport was estimated from cell density at time points during exponential-phase growth
(4 hr and 6 hr). Ccc2D transformed with the deletion allele (orange) and nontransformed ccc2D (green) grew poorly at all temperatures.complementation experiments is not surprising because
proper trafﬁcking is not required for metalation of Fet3p,
the capacity for which is measured by this assay.26 Our
results revealed a modest loss of copper-transport function
(70% of wild-type) in this process for P1386S (Figure 5C).
We speculate that reduced conformational ﬂexibility in
P1386S and T994I ATP7A impedes normal trafﬁcking of
the protein and impairs copper transport into the secretory
pathway for incorporation into nascent cuproproteins.
Superoxide dismutase 1 (MIM 147450), cytochrome
c oxidase (MIM 516030), dopamine-beta-hydroxylase
(MIM 609312), and peptidyl-amidating monooxygenase
(MIM 170270) are cuproenzymes highly relevant to neuro-
logical function.37 Although gain-of-function missense
mutations in superoxide dismutase 1 are implicated in a
familial form of amyotrophic lateral sclerosis involving
upper as well as lower motor-neuron degeneration,38 the
ATP7A mutations we report presumably would reduce,
rather than exaggerate, activity of this enzyme. Even
slightly subnormal activities of certain copper enzymes
might contribute to distal motor neuropathy. For example,350 The American Journal of Human Genetics 86, 343–352, March 1chronic mild deﬁciency of cytochrome c oxidase, an inner
mitochondrial membrane enzyme containing two
subunits that bind copper,39 could gradually induce mito-
chondrial dysfunction in motor neurons.40
The requirement for ATP7A in normal axonal outgrowth
and synaptogenesis has recently been recognized.41 Anter-
ograde axonal ATP7A trafﬁcking is induced by activation of
the N-methyl-D-aspartate receptor that binds glutamate
and might be associated with synaptic release of copper.42
Thus, possible alternative mechanisms for the distal motor
neuropathy in our patients include impaired axonal traf-
ﬁcking, glutamate-mediated excitotoxicity, and altered
synaptic activity of ATP7A. Because the axons and syn-
apses of distal motor neurons extend a considerable dis-
tance from their cell bodies in the spinal cord, we speculate
that these neuronal elements might be autonomous from
their cell bodies in terms of requirements for ATP7A.
The presence of intracellular protein aggregates has been
described in many neurodegenerative diseases,37,38 and
abnormal inclusions have been deﬁned for heterogeneous
forms of inherited distal motor neuropathy, typically2, 2010
identiﬁed when mutant proteins were overexpressed in
mammalian cells.6,7,43–45 It will be useful to formally
exclude or conﬁrm such effects for the ATP7A mutations
we report here.
Thespectrumofgenes implicated in thecausationofdistal
motor neuropathy illustrates the diverse processes involved
in motor neuron physiology.4–7,43,46 The identiﬁcation of
mutations in a gene essential to the homeostasis of trace
metals reveals a new component in this system and further
highlights the critical role of coppermetabolism inneurode-
generation.37 Studies that explore and clarify the potential
mechanisms suggested by our ﬁndings are warranted and
might have relevance to other forms of motor-neuron
disease, including amyotrophic lateral sclerosis. Insights
concerning the functions of ATP7A inmotor neuronsmight
lead to the development of rational treatments for this
newly discovered form of X-linked distal motor neuropathy
and other related disorders in which copper metabolism
plays a previously under-appreciated role.
Supplemental Data
Supplemental data include one ﬁgure and can be found with this
article online at http://www.cell.com/AJHG.Acknowledgments
We thank the patients and family members for their participation
in this study. We thank Rabia Chaudhry and Alison Blake for their
assistance with cell cultures and Jose Centeno for ﬁbroblast copper
measurements. This work was supported by grants from theMotor
Neuron Disease Research Institute of Australia, the National
Health and Medical Research Council of Australia, the Intramural
Research program of the National Institute of Child Health and
Human Development, the Methusalem project of the University
of Antwerp, the Fund for Scientiﬁc Research (FWO-Flanders), the
Medical Foundation Queen Elisabeth (GSKE), and the Interuniver-
sity Attraction Poles program (P6/43) of the Belgian Federal
Science Policy Ofﬁce (BELSPO). J.B. and L.S. are supported by
PhD fellowships of the FWO-Flanders and the University of Ant-
werp, respectively. We thank Professor David Handelsman for
his useful constructive comments on the manuscript.
Received: December 4, 2009
Revised: January 17, 2010
Accepted: January 21, 2010
Published online: February 18, 2010Web Resources
The URLs for data presented herein are as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/omim
University of California, San Francisco Genome Browser, http://
genome.ucsc.edu/References
1. De Jonghe, P., Timmerman, V., and Van Broeckhoven, C.
(1998). 2nd workshop of the European CMT consortium:The Ameri53rd ENMC international workshop on classiﬁcation and
diagnostic guidelines for Charcot-Marie-Tooth type 2 (CMT2-
HMSN II) and distal hereditary motor neuropathy (distal
HMN-Spinal CMT) 26–28 September 1997, Naarden, The
Netherlands. Neuromuscul. Disord. 8, 426–431.
2. Harding, A.E. (1993). Inherited neuronal atrophy and degen-
eration predominantly of lower motor neurons. In Peripheral
Neuropathy, P.J. Dyck, P.K. Thomas, J.W. Grifﬁn, P.A. Low, and
J.F. Poduslo, eds. (Philadelphia: WB Saunders), pp. 1051–1064.
3. Irobi-Devolder, J. (2008). A molecular genetic update of
inherited distal motor neuropathies. Verh. K. Acad. Geneeskd.
Belg. 70, 25–46.
4. Antonellis, A., Ellsworth, R.E., Sambuughin, N., Puls, I., Abel,
A., Lee-Lin, S.Q., Jordanova, A., Kremensky, I., Christodoulou,
K.,Middleton, L.T., et al. (2003). Glycyl tRNA synthetasemuta-
tions in Charcot-Marie-Tooth disease type 2D and distal spinal
muscular atrophy type V. Am. J. Hum. Genet. 72, 1293–1299.
5. Evgrafov, O.V., Mersiyanova, I., Irobi, J., Van Den Bosch, B.L.,
Dierick, I., Leung, C.L., Schagina, O., Verpoorten, N., Van
Impe, K., Fedotov, V., et al. (2004). Mutant small heat-shock
protein 27 causes axonal Charcot-Marie-Tooth disease and
distal hereditary motor neuropathy. Nat. Genet. 36, 602–606.
6. Irobi, J., Van Impe, K., Seeman, P., Jordanova, A., Dierick, I.,
Verpoorten, N., Michalik, A., De Vriendt, E., Jacobs, A., Van
Gerwen, V., et al. (2004). Hot-spot residue in small heat-shock
protein 22 causes distal motor neuropathy. Nat. Genet. 36,
597–601.
7. Puls, I., Oh, S.J., Sumner, C.J., Wallace, K.E., Floeter, M.K.,
Mann, E.A., Kennedy, W.R., Wendelschafer-Crabb, G., Vort-
meyer, A., Powers, R., et al. (2005). Distal spinal and bulbar
muscular atrophy caused by dynactin mutation. Ann. Neurol.
57, 687–694.
8. Takata, R.I., Speck Martins, C.E., Passosbueno, M.R., Abe, K.T.,
Nishimura, A.L., Da Silva, M.D., Monteiro, A. Jr., Lima, M.I.,
Kok, F., and Zatz, M. (2004). A new locus for recessive distal
spinal muscular atrophy at Xq13.1-q21. J. Med. Genet. 41,
224–229.
9. Kennerson, M., Nicholson, G., Kowalski, B., Krajewski, K., El-
Khechen, D., Feely, S., Chu, S., Shy, M., and Garbern, J.
(2009). X-linked distal hereditary motor neuropathy maps to
the DSMAX locus on chromosome Xq13.1-q21. Neurology
72, 246–252.
10. de Bie, P., Muller, P., Wijmenga, C., and Klomp, L.W. (2007).
Molecular pathogenesis of Wilson and Menkes disease: Corre-
lation of mutations withmolecular defects and disease pheno-
types. J. Med. Genet. 44, 673–688.
11. La Fontaine, S., and Mercer, J.F. (2007). Trafﬁcking of the
copper-ATPases, ATP7A and ATP7B: Role in copper homeo-
stasis. Arch. Biochem. Biophys. 463, 149–167.
12. Lutsenko, S., Gupta, A., Burkhead, J.L., and Zuzel, V. (2008).
Cellular multitasking: The dual role of human Cu-ATPases in
cofactor delivery and intracellular copper balance. Arch. Bio-
chem. Biophys. 476, 22–32.
13. Veldhuis, N.A., Gaeth, A.P., Pearson, R.B., Gabriel, K., and
Camakaris, J. (2009). The multi-layered regulation of copper
translocating P-type ATPases. Biometals 22, 177–190.
14. Chelly, J., Tumer, Z., Tonnesen, T., Petterson, A., Ishikawa-
Brush, Y., Tommerup, N., Horn, N., and Monaco, A.P.
(1993). Isolation of a candidate gene for Menkes disease that
encodes a potential heavy metal binding protein. Nat. Genet.
3, 14–19.can Journal of Human Genetics 86, 343–352, March 12, 2010 351
15. Mercer, J.F., Livingston, J., Hall, B., Paynter, J.A., Begy, C.,
Chandrasekharappa, S., Lockhart, P., Grimes, A., Bhave, M.,
Siemieniak, D., et al. (1993). Isolation of a partial candidate
gene for Menkes disease by positional cloning. Nat. Genet.
3, 20–25.
16. Vulpe, C., Levinson, B., Whitney, S., Packman, S., and Gitsch-
ier, J. (1993). Isolation of a candidate gene for Menkes disease
and evidence that it encodes a copper-transporting ATPase.
Nat. Genet. 3, 7–13.
17. Kaler, S.G. (1994). Menkes disease. Adv. Pediatr. 41, 263–304.
18. Kaler, S.G., Gallo, L.K., Proud, V.K., Percy, A.K., Mark, Y., Segal,
N.A., Goldstein, D.S., Holmes, C.S., and Gahl, W.A. (1994).
Occipital horn syndrome and a mild Menkes phenotype asso-
ciated with splice site mutations at the MNK locus. Nat.
Genet. 8, 195–202.
19. Tang, J., Robertson, S., Lem, K.E., Godwin, S.C., and Kaler, S.G.
(2006). Functional copper transport explains neurologic
sparing in occipital horn syndrome. Genet. Med. 8, 711–718.
20. Lem, K.E., Brinster, L.R., Tjurmina, O., Lizak, M., Lal, S., Cen-
teno, J.A., Liu, P.C., Godwin, S.C., and Kaler, S.G. (2007).
Safety of intracerebroventricular copper histidine in adult
rats. Mol. Genet. Metab. 91, 30–36.
21. Ke, B.X., Llanos, R.M., Wright, M., Deal, Y., and Mercer, J.F.
(2006). Alteration of copper physiology in mice overexpress-
ing the human Menkes protein ATP7A. Am. J. Physiol. Regul.
Integr. Comp. Physiol. 290, R1460–R1467.
22. Kaler, S.G., Holmes, C.S., Goldstein, D.S., Tang, J., Godwin,
S.C., Donsante, A., Liew, C.J., Sato, S., and Patronas, N.
(2008). Neonatal diagnosis and treatment of Menkes disease.
N. Engl. J. Med. 358, 605–614.
23. Petris, M.J., Mercer, J.F., Culvenor, J.G., Lockhart, P., Gleeson,
P.A., and Camakaris, J. (1996). Ligand-regulated transport of
the Menkes copper P-type ATPase efﬂux pump from the Golgi
apparatus to the plasma membrane: a novel mechanism of
regulated trafﬁcking. EMBO J. 15, 6084–6095.
24. Payne, A.S., Kelly, E.J., and Gitlin, J.D. (1998). Functional
expression of the Wilson disease protein reveals mislocaliza-
tion and impaired copper-dependent trafﬁcking of the
common H1069Q mutation. Proc. Natl. Acad. Sci. USA 95,
10854–10859.
25. Kim, B.E., Smith, K., Meagher, C.K., and Petris, M.J. (2002).
A conditional mutation affecting localization of the Menkes
disease copper ATPase. Suppression by copper supplementa-
tion. J. Biol. Chem. 277, 44079–44084.
26. Askwith, C.C., de Silva, D., and Kaplan, J. (1996). Molecular
biology of iron acquisition in Saccharomyces cerevisiae. Mol.
Microbiol. 20, 27–34.
27. Donsante, A., Tang, J., Godwin, S.C., Holmes, C.S., Goldstein,
D.S., Bassuk, A., and Kaler, S.G. (2007). Differences in ATP7A
gene expression underlie intrafamilial variability in Menkes
disease/occipital horn syndrome. J. Med. Genet. 44, 492–497.
28. Tang, J., Donsante, A., Desai, V., Patronas, N., and Kaler, S.G.
(2008). Clinical outcomes in Menkes disease patients with
a copper-responsive ATP7A mutation, G727R. Mol. Genet.
Metab. 95, 174–181.
29. Kaler, S.G., Tang, J., Donsante, A., and Kaneski, C.R. (2009).
Translational read-through of a nonsense mutation in
ATP7A impacts treatment outcome in Menkes disease. Ann.
Neurol. 65, 108–113.352 The American Journal of Human Genetics 86, 343–352, March 130. Hsi, G., and Cox, D.W. (2004). A comparison of the mutation
spectra of Menkes disease and Wilson disease. Hum. Genet.
114, 165–172.
31. Goodman, B.P., Bosch, E.P., Ross, M.A., Hoffman-Snyder, C.,
Dodick, D.D., and Smith, B.E. (2009). Clinical and electrodiag-
nostic ﬁndings in copper deﬁciencymyeloneuropathy. J. Neu-
rol. Neurosurg. Psychiatry 80, 524–527.
32. Kelkar, P., Chang, S., and Muley, S.A. (2008). Response to oral
supplementation in copper deﬁciency myeloneuropathy. J.
Clin. Neuromuscul. Dis. 10, 1–3.
33. Kumar, N., Ahlskog, J.E., Klein, C.J., and Port, J.D. (2006).
Imaging features of copper deﬁciency myelopathy: A study
of 25 cases. Neuroradiology 48, 78–83.
34. Spain, R.I., Leist, T.P., and De Sousa, E.A. (2009). When metals
compete: a case of copper-deﬁciency myeloneuropathy and
anemia. Nat. Clin. Pract. Neurol. 5, 106–111.
35. Zara, G., Grassivaro, F., Brocadello, F., Manara, R., and Pesenti,
F.F. (2009). Case of sensory ataxic ganglionopathy-myelop-
athy in copper deﬁciency. J. Neurol. Sci. 277, 184–186.
36. Weihl, C.C., and Lopate, G. (2006). Motor neuron disease
associated with copper deﬁciency. Muscle Nerve 34, 789–793.
37. Desai, V., and Kaler, S.G. (2008). Role of copper in human
neurological disorders. Am. J. Clin. Nutr. 88, 855S–858S.
38. Bruijn, L.I., Miller, T.M., and Cleveland, D.W. (2004). Unravel-
ing the mechanisms involved in motor neuron degeneration
in ALS. Annu. Rev. Neurosci. 27, 723–749.
39. Shoubridge, E.A. (2001). Cytochrome c oxidase deﬁciency.
Am. J. Med. Genet. 106, 46–52.
40. Comi, G.P., Bordoni, A., Salani, S., Franceschina, L., Sciacco,M.,
Prelle,A., Fortunato, F., Zeviani,M.,Napoli, L., Bresolin,N., et al.
(1998). Cytochrome c oxidase subunit I microdeletion in
apatientwithmotor neurondisease.Ann.Neurol.43, 110–116.
41. El Meskini, R., Crabtree, K.L., Cline, L.B., Mains, R.E., Eipper,
B.A., and Ronnett, G.V. (2007). ATP7A (Menkes protein) func-
tions in axonal targeting and synaptogenesis. Mol. Cell. Neu-
rosci. 34, 409–421.
42. Schlief, M.L., Craig, A.M., and Gitlin, J.D. (2005). NMDA
receptor activation mediates copper homeostasis in hippo-
campal neurons. J. Neurosci. 25, 239–246.
43. Windpassinger, C., Auer-Grumbach, M., Irobi, J., Patel, H., Pe-
tek, E., Horl, G., Malli, R., Reed, J.A., Dierick, I., Verpoorten,
N., et al. (2004). Heterozygous missense mutations in BSCL2
are associated with distal hereditary motor neuropathy and
Silver syndrome. Nat. Genet. 36, 271–276.
44. Levy, J.R., Sumner, C.J., Caviston, J.P., Tokito, M.K., Rangana-
than, S., Ligon, L.A., Wallace, K.E., LaMonte, B.H., Harmison,
G.G., Puls, I., et al. (2006). A motor neuron disease-associated
mutation in p150Glued perturbs dynactin function and
induces protein aggregation. J. Cell Biol. 172, 733–745.
45. Maystadt, I., Rezsohazy, R., Barkats,M., Duque, S., Vannuffel, P.,
Remacle, S., Lambert, B., Najimi, M., Sokal, E., Munnich, A.,
etal. (2007). Thenuclear factorkappaB-activatorgenePLEKHG5
ismutated in a formof autosomal recessive lowermotor neuron
disease with childhood onset. Am. J. Hum. Genet. 81, 67–76.
46. Dion, P.A., Daoud, H., and Rouleau, G.A. (2009). Genetics of
motor neuron disorders: new insights into pathogenic mech-
anisms. Nat. Rev. Genet. 10, 769–782.
47. Daube, J.R., and Rubin, D.I. (2009). Clinical Neurophysiology
(Oxford: Oxford University Press).2, 2010
